Absco Therapeutics, Inc.

Boston, MA Doing business as Abscotx

UEI
RYJ8NL66MTP3
CAGE
9WGV3
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
127 Western Ave, Boston, MA 02134, USA
Website
abscotx.com
Founded
2024
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Absco Therapeutics, Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Enhancing solid tumor lmmunotherapy with targeted sirna delivery - abstract to address the significant challenges of… Grant · R43CA306686 National Cancer Institute $406,500
Sbir phase i: image-guided controlled release platform for intratumoral immunoadjuvant delivery -the broader… Grant · 2507269 National Science Foundation $305,000

Quick answers

What is Absco Therapeutics, Inc.'s UEI?

Absco Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is RYJ8NL66MTP3.

What is Absco Therapeutics, Inc.'s CAGE code?

Absco Therapeutics, Inc.'s CAGE code is 9WGV3.

What is Absco Therapeutics, Inc.'s primary NAICS code?

Absco Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Absco Therapeutics, Inc. located?

Absco Therapeutics, Inc.'s physical address in SAM.gov is 127 Western Ave, Boston, MA 02134, USA.

Is Absco Therapeutics, Inc. registered in SAM.gov?

Yes. Absco Therapeutics, Inc.'s SAM.gov registration is active through April 7, 2027.

What is Absco Therapeutics, Inc.'s most recent federal award?

Absco Therapeutics, Inc.'s most recent federal grant award is Enhancing solid tumor lmmunotherapy with targeted sirna delivery - abstract to address the significant challenges of… (R43CA306686), from National Cancer Institute, on September 17, 2025.

On GovTribe

See Absco Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login